
CONTENTS

Foreword	xiii
Preface to the English Edition	xvii
1 General Remarks on Structural, Physical, and Chemical Properties of Fluorinated Compounds	1
1.1 Structural Effects / 2	
1.2 Physical Properties / 3	
1.2.1 Boiling Point / 3	
1.2.2 Surface Tension and Activity / 5	
1.2.3 Polarity-Solubility / 6	
1.2.4 Lipophilicity / 7	
1.3 Effects on Electronic Properties and Reactivity / 9	
1.3.1 Effects of Fluorination on Bond Energies and Reactivity / 9	
1.3.2 Effects of Fluorination on the Electronic Repartition of a Molecule / 10	
1.3.3 Acidity, Basicity, and Hydrogen Bond / 12	
1.3.4 Steric Effects / 15	
1.3.5 Fluorination Effects on the Stability of Reaction Intermediates (Carbocations, Carbanions, and Radicals) / 16	
References / 21	
2 Overview on the Preparation of Fluorinated Compounds	23
2.1 Preparation of Monofluorinated Compounds / 24	
2.1.1 Nucleophilic Fluorination / 24	
2.1.2 Electrophilic Fluorination / 26	
2.1.3 Formation of Carbon–Carbon Bonds Starting from Monofluorinated Synthons / 27	

- 2.2 Preparation of Difluorinated Compounds / 31
 - 2.2.1 Nucleophilic Fluorination / 31
 - 2.2.2 Electrophilic Fluorination / 31
 - 2.2.3 Starting from Di- and Trifluoromethyl Compounds / 31
- 2.3 Preparation of Trifluoromethyl Compounds / 42
 - 2.3.1 Fluorination / 42
 - 2.3.2 Nucleophilic Trifluoromethylation / 42
 - 2.3.3 Electrophilic Trifluoromethylation / 48
 - 2.3.4 Radical Trifluoromethylation / 49
 - 2.3.5 Metal-Catalyzed Trifluoromethylation / 49
 - 2.3.6 Formation of Carbon–Carbon Bonds from Trifluoromethyl Compounds / 50
- 2.4 Synthesis of Perfluoroalkyl Compounds / 61
- References / 62

3 Effects of Fluorine Substitution on Biological Properties

72

- 3.1 Affinity for the Macromolecule Target / 73
 - 3.1.1 Steric Effects / 73
 - 3.1.2 Conformational Changes / 74
 - 3.1.3 Dipolar Interactions and Electric Field / 75
 - 3.1.4 Hydrogen Bonds and Other Weak Interactions / 75
 - 3.1.5 pK_a of Amines / 79
 - 3.1.6 Fluorous Interactions / 80
- 3.2 Absorption / 80
 - 3.2.1 Lipophilicity / 80
 - 3.2.2 pK_a and Solubility / 82
- 3.3 Metabolism / 84
 - 3.3.1 Oxidative Metabolism / 84
 - 3.3.2 Hydrolytic Metabolism / 87
- 3.4 Modification of Chemical Reactivity: Enzyme Inhibitors / 89
 - 3.4.1 Analogue of Substrates as Inhibitors / 90
 - 3.4.2 Inhibition by Stabilization or Destabilization of Intermediates of Biological Processes / 91
 - 3.4.3 Irreversible Inhibition with Mechanism-Based Inhibitors (Suicide Substrates) / 93
- References / 95

4 Fluorinated Analogues of Natural Products **99**

- 4.1 Fluorinated Products in Nature / 99
- 4.2 Steroids / 101
 - 4.2.1 Corticosteroids / 101
 - 4.2.2 Steroids with Trifluoromethyl Groups in Angular Position / 103
 - 4.2.3 Fluorinated Analogues of Metabolites of Vitamin D₃ / 105
 - 4.2.4 Other Fluorinated Steroids / 108
- 4.3 Terpenes / 108
 - 4.3.1 Artemisinin / 108
 - 4.3.2 Taxol / 110
- 4.4 Pigments and Vitamins / 111
 - 4.4.1 Retinoids / 111
 - 4.4.2 Carotenoids / 115
 - 4.4.3 Vitamin D / 116
 - 4.4.4 Vitamins E and K / 116
 - 4.4.5 Porphyrins / 117
- 4.5 Lipids and Prostanoids / 119
- 4.6 Pheromones and Toxins / 125
- 4.7 Alkaloids / 129
 - 4.7.1 *Vinca* Alkaloids / 129
 - 4.7.2 Cinchona Alkaloids / 131
 - 4.7.3 Camptothecin / 132
 - 4.7.4 Other Fluorinated Alkaloids / 133
- 4.8 Macrolides / 133
 - 4.8.1 Epothilone / 133
 - 4.8.2 Erythromycin / 134
 - 4.8.3 Amphotericin B / 135
 - 4.8.4 Avermectin / 136
- 4.9 Anthracyclines / 138
- References / 139

5 Fluorinated Derivatives of α -Amino Acids and Proteins **146**

- 5.1 Fluorinated Aliphatic Amino Acids / 147
 - 5.1.1 Alanines / 147

- 5.1.2 Valines, Leucines, and Isoleucines / 151
- 5.1.3 Prolines / 154
- 5.2 Aromatic Amino Acids: Phenylalanine, Tyrosine, Histidine, and Tryptophan / 156
- 5.3 Functional Fluorinated Amino Acids / 158
 - 5.3.1 Serines and Threonines / 158
 - 5.3.2 Aspartic Acids and Arginines / 159
 - 5.3.3 Glutamic Acids and Glutamines / 161
 - 5.3.4 Lysine, Ornithine, and Arginine / 161
 - 5.3.5 Cysteines and Methionines / 163
- 5.4 α -Fluoroalkyl Amino Acids / 164
 - 5.4.1 Mono- and Difluoromethyl Amino Acids / 165
 - 5.4.2 α -Trifluoromethyl Amino Acids / 165
- 5.5 Incorporation of Fluorinated Amino Acids into Peptides and Proteins / 169
 - 5.5.1 Polypeptides / 169
 - 5.5.2 Proteins / 171
- References / 173

6 Saccharidic Fluorinated Derivatives

180

- 6.1 Glycosyl Fluorides / 181
- 6.2 Mono- and Difluorinated Analogues of Sugars / 181
 - 6.2.1 Fluorinated Furanoses and Nucleosides / 181
 - 6.2.2 Fluorinated Pyranoses / 190
- 6.3 Fluoromethyl Derivatives of Sugars / 197
 - 6.3.1 Difluorovinyl Compounds / 197
 - 6.3.2 Difluoromethylene-*C*-Glycosides / 197
 - 6.3.3 *C*-Difluoromethyl Glycosides / 200
 - 6.3.4 Trifluoromethylated Sugars / 202
- 6.4 Perfluoroalkylated Sugars / 209
 - 6.4.1 Preparation of *C*-Perfluoroalkyl Sugars / 210
 - 6.4.2 *O*- and *S*-Fluoroalkyl Glycosides / 211
 - 6.4.3 Applications of Amphiphilic Fluoroalkyl Sugars / 214
- References / 216

7 Inhibition of Enzymes by Fluorinated Compounds 223

- 7.1 Substrate Analogues / 225
 - 7.1.1 Fluorine Replaces a Hydrogen Involved in the Catalytic Cycle / 225
 - 7.1.2 Fluorine Replaces a Hydroxyl / 227
 - 7.1.3 Fluorinated Analogues of Substrates in Which Fluorine is Not Directly Involved in the Inhibition / 230
- 7.2 Destabilization of Reaction Intermediates (or of Transition States) of Enzymatic Processes by Fluorinated Groups / 242
 - 7.2.1 Prenyl Transfer / 242
 - 7.2.2 Inhibition of Glycosidases and Glycosyltransferases / 242
 - 7.2.3 Inhibition of UDP-GlcNAC Enolpyruvyltransferase (MurZ) / 244
 - 7.2.4 Enolpyruvate Shikimate Phosphate Synthase (EPSPS) / 245
- 7.3 Inhibitors that are Analogues of the Transition State: Di- and Trifluoromethyl Ketones / 246
 - 7.3.1 Serine Enzymes / 246
 - 7.3.2 Inhibition of Aspartyl Enzymes / 250
 - 7.3.3 Inhibition of Metalloproteases / 254
 - 7.3.4 Cysteine Protease and Thiol Enzymes / 254
- 7.4 Mechanism-Based Inhibitors / 256
 - 7.4.1 Inhibition of Pyridoxal Phosphate Enzymes / 257
 - 7.4.2 Thymidylate Synthase / 261
 - 7.4.3 Inhibition of Monoamine Oxidases / 262
 - 7.4.4 D-Ala-D-Ala Dipeptidase (VanX) / 264
 - 7.4.5 Inhibition of Ribonucleotide Diphosphate Reductase / 264
 - 7.4.6 Inhibition of S-Adenosylhomocysteine Hydrolase / 265
 - 7.4.7 Inhibition of Cytidine-5'-diphosphate-D-Glucose 4,6-Dehydratase (CDP D-Glucose 4,6-Dehydratase) / 266
 - 7.4.8 Other Irreversible Inhibitors / 267
- 7.5 Fluorinated Inhibitors Involving a Still Unknown Mechanism / 268
 - 7.5.1 Inhibition of the Steroid C₁₇₍₂₀₎lyase / 268
 - 7.5.2 Phosphatidylinositol Phospholipase C (PI-PLC) / 268
 - 7.5.3 Inhibition of the Protein of Transfer of Cholesteryl Esters / 269
 - 7.5.4 β -Fluoropolyamines as Inhibitors of the Biosynthesis of Polyamines / 270
 - 7.5.5 Inhibition of the Biosynthesis of Cholesterol / 272

References / 272

8 Fluorinated Drugs

- 8.1 Antitumor and Antiviral Fluorinated Drugs / 280
 - 8.1.1 Fluoronucleosides / 280
 - 8.1.2 Other Antitumor and Antiviral Drugs / 284
- 8.2 Anti-infectious Drugs / 289
 - 8.2.1 Fluorinated Antibiotic Drugs / 289
 - 8.2.2 Antifungal Drugs / 297
 - 8.2.3 Fluorinated Drugs for Parasitic Diseases / 299
- 8.3 Drugs for CNS Disorders / 300
 - 8.3.1 Neuroleptics / 300
 - 8.3.2 Drugs for Depressive Disorders / 302
 - 8.3.3 Anxiolytics and Sedatives / 304
 - 8.3.4 Other Drugs for CNS Disorders / 304
- 8.4 Drugs of Inflammatory and Immunity Disorders / 308
 - 8.4.1 Fluorocorticosteroids / 308
 - 8.4.2 H₁ Antagonist Antiallergics / 314
 - 8.4.3 Drugs for Asthma and Respiratory Disorders / 314
 - 8.4.4 Analgesic and Antiarthritic Drugs / 316
- 8.5 Drugs for Cardiovascular Disorders / 320
 - 8.5.1 Cholesterol Lowering Drugs / 320
 - 8.5.2 Drugs for Hypertension / 321
 - 8.5.3 Drugs for Arrhythmias / 324
 - 8.5.4 Antithrombosis and Anticoagulant Fluorinated Agents / 324
- 8.6 Drugs for Gastrointestinal Disorders / 325
 - 8.6.1 Prevention and Treatment of Ulcer / 325
 - 8.6.2 Antiemetic Agents / 326
 - 8.6.3 Drugs for Bowel Disorders / 327
- 8.7 Drugs for Endocrine and Metabolic Disorders / 327
 - 8.7.1 Drugs Acting on Steroid Hormone Receptors / 327
 - 8.7.2 Drugs for Benign Prostatic Hypertrophy (BPH) / 329
 - 8.7.3 Drugs for Other Urologic Disorders / 330
 - 8.7.4 Drugs for Calcemia Disorders / 331
 - 8.7.5 Drugs for Diabetes / 331
 - 8.7.6 Drugs for Hepatic Disorders / 333
- 8.8 Miscellaneous / 334
 - 8.8.1 Drugs for Ophthalmic Disorders / 334

- 8.8.2 Drugs for Genetic Disease / 334
- 8.8.3 Contrast and Diagnostic Agents / 334
- 8.9 Highly Fluorinated Compounds with Clinical Uses / 335
 - 8.9.1 General Anesthetics / 335
 - 8.9.2 Therapeutic Uses of Perfluorocarbons / 338
- 8.10 Fluorinated Functions and Motifs in Medicinal Chemistry / 339
 - 8.10.1 Fluorinated Ethers / 339
 - 8.10.2 Fluorinated Alcohols and Amines / 340
 - 8.10.3 Fluorinated Ketones / 340
 - 8.10.4 Fluoroalkyl Groups / 341
- Appendix: INN and Trademark Names / 342
- References / 347

Index**353**

